Medizinische Hochschule Hannover AAV2 Gene Therapy Vector Patent

The EPO published application EP4107257A1 on April 15, 2026, covering a viral vector particle based on AAV2 for gene therapy applications. The applicant is Medizinische Hochschule Hannover, a German medical university. Four inventors are named: Thomas THUM, Hildegard BÜNING, Laura SANTER, and Christian BÄR. The application is classified under IPC codes C12N 7/00, C12N 15/864, and C07K 14/005, indicating applications in virology, gene therapy, and viral protein technology.

Parties seeking to develop or commercialize AAV2-based gene therapy vectors should review this application to assess potential freedom-to-operate considerations. Competitors in the gene therapy vector space may need to evaluate whether the claimed viral vector particle design overlaps with their own research programs. The publication of the application marks the beginning of the opposition period during which third parties may file observations before the EPO completes examination.